Spots Global Cancer Trial Database for A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Official Title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Study ID: NCT02937675
Conditions
Interventions
Study Description
Brief Summary: This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of Tomivosertib (eFT-508). The study will evaluate oral daily administration of Tomivosertib (eFT-508). Treatment and study subject evaluation will be performed in 21-day cycles.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
Florida Cancer Specialist, Sarasota, Florida, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Hospital, Detroit, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Rochester, Rochester, New York, United States
Gabrail Cancer Center Research, Canton, Ohio, United States
Baylor Scott & White Research Institute, Dallas, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
West Virginia University, Morgantown, West Virginia, United States
Contact Details
Name: Jeremy Barton, MD
Affiliation: CMO
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
